Effects of Niacin on Glucose Control in Patients with Dyslipidemia

Goldberg, Ronald B.; Jacobson, Terry A.
April 2008
Mayo Clinic Proceedings;Apr2008, Vol. 83 Issue 4, p470
Academic Journal
Niacin (nicotinic acid), the most effective available pharmacotherapy for Increasing high-density lipoprotein cholesterol, also lowers triglycerides and hence may be useful, alone or In combination with hydroxymethylglutaryl coenzyme A reductase inhibitors (statins), to offset residual cardiovascular risk in patients with mixed or diabetic dyslipidemia. We conducted a review of published consensus guidelines since 2000 and an English-language PubMed search of prospective, randomized controlled trials and open-label studies from January 1, 1990, through December 31, 2007, concerning the effects of niacin, alone or in combination with statins, on glycemic regulation In dyslipidemic patients (with or without diabetes mellitus). For search terms, we used the title words niacin or nicotinic acid and key words including diabetes, diabetic, dyslipidemia, glucose, glycemic, HbA1c, hemoglobin, hyperglycemia, human, Insulin, postprandial, and safety. Retrospective and observational studies, case reports, and case studies were excluded. On the basis of our analysis, the effects of niacin (≤5 g/d), alone or in combination with statins, on fasting glucose (an increase of 4%-5%) and hemoglobin A1c levels (an increase of ≤0.3%) are modest, transient or reversible, and typically amenable to adjustments In oral hypoglycemic regimens without discontinuing niacin. Niacin therapy was Infrequently associated with incident diabetes or the need for new insulin prescriptions. Studies showed important clinical benefits of niacin or niacin-statin regimens despite modest effects on glucose control. On a population basis, significant reductions in incidences of cardiovascular events and the degree of atherosclerotic progression associated with long-term niacin (or niacin-statin) therapy in patients with diabetic dyslipidemia outweigh the typically mild effects of this therapy on glycemic regulation. Consensus guidelines recommend monitoring glycemic control after initiating niacin treatment or increasing its dosage.


Related Articles

  • BETA-SITOSTEROL: AN ANTI-INFLAMMATORY AND ANTI-CHOLESTEROL PLANT. Haas, Robert // Life Extension;Mar2010, Vol. 16 Issue 3, Special section p5 

    The article discusses research into the use of beta-sitosterol for the treatment of inflammation and high cholesterol. The natural cholesterol-lowering compounds include policosanol and niacin. The author notes that natural compounds can be an effective alternative to the use of high-dose statin...

  • Niacin Beats Ezetimibe Head to Head.  // Internal Medicine Alert;12/15/2009 Pharmacology Watch, p1 

    The article presents a study which examines the impact of statin and niacin on the level of high-density lipoprotein-cholesterol (HDL-C).

  • Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. Goldie, Christina; Taylor, Allen J.; Nguyen, Peter; McCoy, Cody; Xue-Qiao Zhao; Preiss, David; Zhao, Xue-Qiao // Heart;Feb2016, Vol. 102 Issue 3, p198 

    Objective: Previous studies have suggested that niacin treatment raises glucose levels in patients with diabetes and may increase the risk of developing diabetes. We undertook a meta-analysis of published and unpublished data from randomised trials to confirm whether an association...

  • Diabetic dyslipidemia: A practical guide to therapy. Tovar, John M.; Bazaldua, Oralia V.; Loffredo, Alexandra // Journal of Family Practice;Jun2008, Vol. 57 Issue 6, p377 

    The article outlines the research conducted on the medications used in effectively treating diabetic dyslipidemia patients in the U.S. Figures reveal that among 7000 patients with diabetes, 72% were treated with hyperglycemia and 64% for hypertension, but only 28% were treated for dyslipidemia....

  • Statins and secondary prevention of coronary heart disease. Ahmed, Mehboub; Griffiths, Peter // British Journal of Community Nursing;April2004, Vol. 9 Issue 4, p160 

    Assesses the effectiveness of lipid-lowering treatments, such as statins, in the secondary prevention of myocardial infarction (MI). Trials demonstrating that statins had a clear and consistent effect in significantly reducing the risk of MI; Approximate decline in MI produced from three trials.

  • Retrospective analysis demonstrates that switching statins hinders treatment compliance, persistence.  // Formulary;Jan2006, Vol. 41 Issue 1, p36 

    The article reports on the results of a retrospective analysis of patients who have switched statins. It is suggested that even if switching statins is a necessary tool of drug therapy for lipid management, it should be done with carefulness. The difference in persistence between switchers and...

  • Add-on statin in postcode lottery row.  // Pulse;9/22/2003, Vol. 63 Issue 38, p4 

    Reports on the availability of add-on statin ezetimibe in Scotland. Details of an Executive decision to recommend the use of the drug in patient with high cholesterol levels; Issues related to statin prescribing.

  • BETTER THAN STATINS.  // Nutrition Action Health Letter;May2002, Vol. 29 Issue 4, p6 

    Reports on the results of a study on the use of statin drugs and a healthy diet to lower low-density lipoprotein cholesterol.

  • Statins and cardiac benefits.  // Medical Marketing & Media;Oct2001, Vol. 36 Issue 10, p19 

    Examines the drug properties of statins beyond diminishing cholesterol levels. Differences in the reactions of the drugs usage in terms of vascular disease; Reproduction of platelet activity and aggregation; Increase of bone formation and mineral density.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics